🇺🇸 FDA
Pipeline program

VALACICLOVIR ARROW 500 mg, comprimé pelliculé sécable, PREVYMIS PLACEBO, VALACICLOVIR PLACEBO, PREVYMIS 240 mg film-coated tablets

APHP180592

Phase 3 small_molecule active

Quick answer

VALACICLOVIR ARROW 500 mg, comprimé pelliculé sécable, PREVYMIS PLACEBO, VALACICLOVIR PLACEBO, PREVYMIS 240 mg film-coated tablets for Diseases [C] - Virus Diseases [C02] is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Diseases [C] - Virus Diseases [C02]
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials